-
Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of Enhertu in HER2-positive early breast cancer
-
TROPION-Breast02 data will demonstrate potential of Datroway in metastatic triple-negative breast cancer, most aggressive subtype
-
POTOMAC disease-free survival and MATTERHORN survival results will showcase benefit of Imfinzi in early bladder and gastric cancers
13 October 2025--AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025.
More than 95 abstracts will feature nine approved and nine potential new medicines from the Company including two abstracts featured in a late-breaking Presidential Symposium and 26 oral presentations.
Key presentations include:
DESTINY-Breast11 Phase III trial of Enhertu followed by paclitaxel, trastuzumab and pertuzumab (THP) when used in the neoadjuvant setting in patients with high-risk, locally advanced HER2-positive early-stage breast cancer (Presidential Symposium 1 Abstract #291O).
DESTINY-Breast05 Phase III trial of Enhertu (trastuzumab deruxtecan) as post-neoadjuvant therapy in patients with HER2-positive early breast cancer with high risk of disease recurrence (Presidential Symposium 1 Abstract #LBA1).
TROPION-Breast02 Phase III trial of Datroway (datopotamab deruxtecan) as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option (Proffered Paper Abstract #LBA21).
POTOMAC Phase III trial of Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) (Proffered Paper Abstract #LBA108).
MATTERHORN: Final overall survival (OS) results from the Phase III trial of perioperative Imfinzi (durvalumab) plus FLOT chemotherapy in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers (Proffered Paper Abstract #LBA81).
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “We are advancing a broad portfolio of new treatments to transform patient care in breast cancer and sharing meaningful progress at ESMO with data from TROPION-Breast02, DESTINY-Breast11 and DESTINY-Breast05. We are also sharing data from our next wave of potential new Oncology medicines including saruparib in combination with novel hormonal agents in prostate cancer, our folate receptor targeted antibody drug conjugate torvu-sam in ovarian cancer, and rilvegostomig in non-small cell lung cancer.”
Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “The momentum of our industry-leading oncology portfolio continues with presentations of the first data from four major pivotal trials at this year’s ESMO. Beyond the key data in breast cancer for Enhertu and Datroway, the POTOMAC results for Imfinzi demonstrate the benefits of treating early-stage bladder cancer with immunotherapy and illustrate our strategy to bring novel treatments to early cancer settings where patients can benefit most.”
Additional highlights include:
FONTANA Phase I/IIa first-in-human trial of AZD5335, a folate receptor α (FRα)-targeting antibody drug conjugate, in patients with platinum-resistant recurrent ovarian cancer (Mini Oral Abstract #1065MO).
PETRANHA Phase I/II trial of saruparib plus androgen receptor pathway inhibitors in patients with metastatic prostate cancer (Mini Oral Abstract #2384MO).
ARTEMIDE-01 Phase I/II trial of rilvegostomig in patients with checkpoint inhibitor-naïve metastatic NSCLC (Mini Oral Abstract #1853MO).
FLAURA2: Exploratory OS analysis of patients with poor prognostic factors in the FLAURA2 Phase III trial of Tagrisso (osimertinib) plus chemotherapy in advanced EGFR-mutated non-small cell lung cancer (NSCLC) (Proffered Paper Abstract #LBA77).
CAPItello-281: Phase III trial of Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC) (Proffered Paper Abstract #2383O).
TROPION-PanTumor03: First results from the bladder cancer cohort of the TROPION-PanTumor03 Phase II trial of Datroway plus rilvegostomig (Mini Oral Abstract #3072MO).
BEGONIA: Final results from the BEGONIA Phase Ib/II trial of Datroway plus Imfinzi in patients with previously untreated unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) (Mini Oral Abstract #555MO).
AstraZeneca is collaborating with Daiichi Sankyo to develop and commercialise Enhertu and Datroway, collaborating with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise Lynparza (olaparib), and collaborating with HUTCHMED to develop and commercialise Orpathys (savolitinib). Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902.
Key AstraZeneca presentations during ESMO Congress 20251
1 More than 90 abstracts at ESMO Congress 2025 will feature AstraZeneca medicines and pipeline molecules
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.